Objectives. SSc-pulmonary arterial hypertension (SSc-PAH) is associated with worse response to therapy and survival when compared with idiopathic PAH. It is suggested that the vasculopathy in SSc may involve postcapillary pulmonary venules resulting in pulmonary veno-occlusive disease (PVOD). This may underlie the lower gas transfer and worse outcome on therapy. We sought to test whether CT signs of PVOD (CTS-PVOD) were frequent in SSc-PAH and whether they were associated with pulmonary oedema on therapy and worse survival.
Introduction
Pulmonary veno-occlusive disease (PVOD) is a rare form of pulmonary hypertension (PH) with a prevalence of 0.10.2/million persons per year [1] . It is characterized histologically by fibrotic occlusion of post-capillary venules. Pulmonary arterial hypertension (PAH) is a vasculopathy of the precapillary arterioles without severe venous involvement. While pulmonary vasodilators are generally well tolerated in PAH and form the mainstay of therapy [2] , their use in PVOD is potentially dangerous, as dilating the arterial tree in the face of fixed venous obstruction may precipitate non-cardiogenic pulmonary oedema [3] .
The diagnosis of PVOD in life requires open lung biopsy, but this is unsafe in most patients with PH. Non-invasive cross-sectional imaging, for example, CT, is the preferred diagnostic modality [4] . Resten and colleagues [5] showed that a triad of radiological findings on CT chest-centrilobular ground glass opacities, interlobular septal thickening and lymph node enlargement-were significantly more frequent in patients with histopathologically confirmed PVOD than in those with idiopathic, familial or anorexigen-associated PAH and that these patients had a worse prognosis [6] .
PAH complicates up to 12% of cases of SSc and is the major cause of death in these individuals [7] . Patients with SSc-PAH have less favourable outcomes despite PAHspecific therapy than those with idiopathic PAH [8] . A possible explanation is that radiological PVOD is more common in SSc-PAH than in idiopathic PAH, and thus that the poorer outcomes may be due in part to unmasking of PVOD by vasodilator therapy [9] . Histological support for this concept was provided by Dorfmü ller et al. [10] whose analyses of biopsy samples from four patients with SSc-PAH demonstrated smooth muscle actin-positive staining lesions of the preseptal veins, highly suggestive of PVOD.
Gü nther et al. [11] further reported that >60% of SSc-PAH patients had two or more CT signs of PVOD (CTS-PVOD) and that half of these individuals developed pulmonary oedema following PAH-specific therapies and had worse survival than did patients with fewer CTS-PVOD.
Our centre manages more than 500 patients with SSc-PAH. We have observed pulmonary oedema in response to PAH-specific therapies, but this appears to be uncommon despite routine aggressive use of combination therapy and prostanoids. We therefore wished to explore more formally the prevalence of radiological and clinical PVOD in an unselected population.
Methods

Patients
From 500 patients with SSc referred for evaluation to the National Pulmonary Hypertension Service at the Royal Free Hospital between 2005 and 2013, 195 were identified with available chest CT imaging performed either at the time of diagnosis of PH, or during follow-up where no interval change in CT findings was found compared with an available scan from before the diagnosis of PH. All patients underwent right heart catheterization. All patients were euvolaemic. Where patients were suspected of having left heart disease (in particular if the left atrium was enlarged on transthoracic echocardiography), left ventricular end diastolic pressure was assessed and/or cardiac MRI performed to exclude those with postcapillary PH. Patients were excluded from further evaluation if: mean pulmonary artery pressure (mPAP) was <25 mmHg (n = 87); pulmonary capillary wedge pressure was >15 mmHg (n = 3); interstitial lung disease was identified (n = 34); or the quality of CT imaging was inadequate (n = 5). Sixty-six patients were included in the final analysis. Ethical approval and informed patient consent were not required for this study.
Clinical assessment
Clinical variables recorded at baseline included WHO functional class and 6 min walk distance (6MWD). One patient was too unwell to perform the 6MWD, and so a value of 0 m was recorded. Autoantibody profile, NT-Pro brain natriuretic peptide (NT-ProBNP) and serum creatinine were noted. Pulmonary function testing was performed. Haemodynamic measurements included mPAP, pulmonary capillary wedge pressure, right atrial pressure, pulmonary vascular resistance and cardiac index.
Evaluation of CT thorax
All patients underwent CT chest using either a Philips Brilliance 64 (Amsterdam, Netherlands), General Electric Lightspeed 4 slice (Boston, Massachusetts, United States) or Toshiba Aquilion Once 320 slice volume scanner (Tokyo, Japan). Scan protocols included volumetric and non-volumetric high resolution CT scans with supine inspiratory/expiratory acquisitions and prone inspiratory acquisitions; CT pulmonary angiography; and volumetric unenhanced, arterial and portal venous phase scans. Slice thickness, tube current/kilovoltage, filters and reconstruction algorithms varied according to the protocol and scanner used. The scans were read by two radiologists: J.A.H., a consultant thoracic and general radiologist, and S.A., a final year subspecialty training registrar in cardiothoracic imaging. Both were blinded to the pulmonary pressures and clinical indications for the scans. Each scan was scored using a system with both quantitative and qualitative components (supplementary Table S1 , available at Rheumatology Online). There was 100% agreement between the radiologists with respect to the number of CTS-PVOD in each scan. If there was minor disagreement with respect to other scan findings, a discussion resulted in 100% agreement. Owing to the nature of the radiological findings assessed, it was not felt by either radiologist that the type of scan had any impact upon interpretation. Five patients were excluded from the study due to suboptimal imaging such that one or more of the triad of centrilobular ground glass opacities, interlobular septal thickening and lymph node enlargement could not be assessed.
Patients were divided into two groups according to the number of CTS-PVOD (41 or 52). If a patient had >20% interstitial lung disease, defined as > 20% parenchymal involvement in the fibrotic process, severe emphysema or combined pulmonary fibrosis and emphysema, they were considered to have SSc-PH secondary to lung disease and were excluded from the analysis. In the absence of significant radiological lung disease, as long as airways disease (FEV1 <50%) was not present, then a diagnosis of SSc-PAH was made.
Treatment
Following a diagnosis of PAH, all patients were commenced on PAH-specific therapy, as per multisociety guidelines. These included phosphodiesterase-5 inhibitors, endothelin receptor antagonists and prostanoids. Patients were followed until death or date of censorship. Incidence of pulmonary oedema following initiation of therapy was determined by case note and radiography review.
Survival data
Survival data were collected on all patients and were drawn from the National Health Service Primary Care Mortality Database, an online database that is updated monthly and holds mortality data for each deceased patient in England and Wales. The censorship date was 1 March 2015.
Statistical analysis
Statistical analysis was performed using an unpaired Student's t test to compare mean values between groups (41 CTS-PVOD vs 52 CTS-PVOD), and the chisquare test was used to compare categorical data between groups. For skewed data, such as NT-ProBNP and right atrial pressure, we used a logarithm transformation to satisfy the normality assumption of the statistical methods. Data are presented as the mean (S.D.), or frequency (percentage) unless otherwise stated. Survival status was evaluated using the KaplanMeier method. Univariate Cox regression analysis was used to compare survival between the two groups and also to evaluate separately survival for European Society of Cardiology/ European Respiratory Society determinants of prognosis [12] . A multiple Cox regression model was performed to adjust the comparison between the two groups for the effect of known risk factors including age and sex. P < 0.05 was considered significant.
Results
Demographic data at baseline
Demographic and clinical characteristics of SSc-PAH patients with 41 CTS-PVOD (n = 59) and SSc-PAH with 52 CTS-PVOD (n = 7) are shown in Table 1 . The mean age of all patients was 63 (12) years (range 3483 years). The majority (89%) were female. Limited cutaneous SSc was present in 89% and the remainder had diffuse SSc.
Functional and serological characteristics WHO functional class, 6MWD and the results of pulmonary function tests are shown in Table 1 . The majority were functional class III with no difference between the 41 CTS-PVOD and 52 CTS-PVOD groups. The mean 6MWD was 253 (124) m, again with no difference between groups. Analysis of pulmonary function shows that there was a non-significantly lower FVC in those with 52 CTS- PVOD and that gas transfer, while numerically lower, was not reduced in those with 52 CTS-PVOD. Median NTProBNP and creatinine tended to be higher in patients with 52 CTS-PVOD.
Cardiac catheter data
Haemodynamic parameters were very similar between groups ( Table 1 ). The mPAP in the total population was 39 (11) mmHg with a mean wedge of 11 (3) mmHg. Cardiac index was preserved at 2.7 (1.0) l/min/m 2 .
Patients with 52 CTS-PVOD were more hypoxic than those with 41 CTS-PVOD (P < 0.01).
Prevalence of individual CTS-PVOD
Forty-eight patients (73%) exhibited no CTS-PVOD. Eleven patients (17%) had one CT feature of PVOD, six patients (9%) had two CTS-PVOD and just one patient (2%) exhibited all three CTS-PVOD. With respect to individual CT features of PVOD: 13 patients (20%) had lymph node enlargement, 10 (15%) had interlobular septal thickening and three (5%) had centrilobular ground glass opacities.
Analysis of CT thorax
Radiographic characteristics of SSc-PAH patients are shown in supplementary Table S2 , available at Rheumatology Online. The mean pulmonary artery diameter was similar between the two groups, at 31 mm. Four patients (7%) with 41 CTS-PVOD and three patients (43%) with 52 CTS-PVOD had pleural effusions, making this the only radiological sign that was more prevalent in patients with 52 CTS-PVOD (P < 0.01). Fifteen patients (25%) with 41 CTS-PVOD and four patients (57%) with 52 CTS-PVOD had pericardial effusions but this difference did not reach statistical significance (P = 0.08). Dilatation of the oesophagus was common across the entire population with a prevalence ranging from 22 to 43%, but no significant difference was noted with respect to number of CTS-PVOD (P = 0.22).
Incidence of pulmonary oedema following vasodilator therapy
The overall incidence of pulmonary oedema on PAHspecific therapy was low at 6%. The baseline parameters and disease course of these four patients are shown in Table 2 . Fifty-nine patients with 41 CTS-PVOD received PAH-specific therapy. Of these, two (3%) developed pulmonary oedema. Seven patients with 52 CTS-PVOD received PAH-specific therapy; two of these (29%) developed pulmonary oedema (P = 0.008). With regard to the four patients who developed clinical PVOD, one received sildenafil only, one received bosentan only and two received oral combination therapy. The median time between starting PAH-specific therapy and the development of pulmonary oedema was 31 days (range 3090 days). Management of pulmonary oedema included admission for intravenous diuresis and withdrawal of PAHspecific therapies.
Prostanoid therapy A total of seven patients (11%) had or developed at least one of the pre-specified criteria for prostanoid therapy, one at the time of diagnosis. Six patients were in the 41 CTS-PVOD group and one was in the 52 CTS-PVOD group. None of these patients developed clinical PVOD in response to prostanoid therapy.
Autoantibody status
The results of autoantibody status are shown in Table 3 .
The commonest autoantibody in those with 41 CTS-PVOD and in those with 52 CTS-PVOD was anticentromere. This was the autoantibody present in all four patients with clinical PVOD. However, given that ACAs were also present in 58% of patients without clinical PVOD, no association between autoantibody status and PVOD can be drawn from this study (P = 0.10).
Survival
Patients presenting with 52 CTS-PVOD had a trend toward more rapid progression to death than did patients with 41 CTS-PVOD (Fig. 1) . At the time of censoring, 32 patients had died and 34 were still alive. SSc-PAH patients with 41 feature of PVOD had a mean nonadjusted survival of 5.9 years. SSc-PAH patients with 52
features of PVOD had a mean non-adjusted survival of 2.8 years.
On univariate analysis 52 CTS-PVOD was associated with a trend towards worse survival (hazard ratio (HR) = 2.57, 95% CI: 0.97, 6.80; P = 0.06; Table 4 ). However on multivariable analysis, when European Society of Cardiology/European Respiratory Society prognostic risk factors are also considered, 52 CTS-PVOD is not associated with worse survival (HR = 1.03, 95% CI: 0.30, 3.48; P = 0.97; Table 5 ).
Discussion
This blinded retrospective analysis of the CT scans of 66 unselected patients with SSc-PAH sought to determine whether CTS-PVOD are common and whether they predict pulmonary oedema on therapy and worse survival. We found that radiological signs of PVOD were less www.rheumatology.oxfordjournals.org common in SSc-PAH than previous reports suggest. Two or more CT signs of PVOD were associated with a relatively greater incidence of pulmonary oedema on therapy compared with patients with none or one CT sign of PVOD. There is a trend towards reduced survival in patients with 52 CT features of PVOD; however, this was not an independent predictor when other risk factors are considered. The data presented suggest that a subpopulation with survival comparable to idiopathic PAH can be identified: those with 41 CTS-PVOD. Among such patients 5-year survival exceeds 50% and pulmonary oedema on therapy is rare. Gü nther et al. [11] evaluated the CT scans of 26 patients with SSc-PAH referred to their transplant service because of an inadequate response to therapy. Hence they were studying a selected group of non-responders. In their report, 62% of patients had at least two CTS-PVOD whereas in our study only 11% did. The demographic, clinical and haemodynamic characteristics of the two populations are similar, intriguingly with the exception of better performance on the 6 min walk test [329 (89) m (in that study) vs 253 (124) m in our population].
Rajaram and colleagues [13] evaluated CT pulmonary angiograms of 95 patients with SSc-PAH and found that 36% had centrilobular ground glass opacities, a quarter had lymph node enlargement and over a fifth had interlobular septal thickening. These findings contrast with ours, but interestingly, patients with idiopathic PAH had a greater frequency of centrilobular ground glass opacities and interlobular septal thickening than did patients with SSc-PAH. Taken together, it does not appear that CTS-PVOD are more common in SSc-PAH than in idiopathic PAH.
All patients in our study received PAH-specific therapy. Twenty-nine per cent of our patients with at least two CTS-PVOD developed pulmonary oedema on therapy. Gü nther et al. [11] reported a higher incidence (50%) of pulmonary oedema in response to PAH-specific therapy among their 16 patients with at least two radiographic signs of PVOD. This difference between our findings may be due to the small sample size and differences in therapeutic aggression. In terms of prostanoid use, half the patients in the study of Gü nther et al. [11] who developed pulmonary oedema were receiving them, while only one of our patients with 52 CTS-PVOD did. Several clinical trials have examined the effect of prostanoids on PAH cohorts that include SSc-PAH [1416] and these have reported pulmonary oedema as an infrequent event in the SSc-PAH population.
On univariate analysis, 52 CTS-PVOD was associated with a trend towards worse outcome; however, as this subgroup was older and had higher baseline NTProBNP, the trend was non-significant on multivariable analysis. What cannot be determined from the current study is whether older SSc patients are more likely to develop PVOD and whether the presence of venous extension of the vasculopathy increases right ventricular strain, hence causing a greater elevation of NT-ProBNP.
We identified four patients, two with 41 CTS-PVOD and two with 52 CTS-PVOD, who developed clinical PVOD, that is, pulmonary oedema in response to vasodilator therapy. The clinical characteristics of these patients are shown in Table 2 . While it is not possible to draw robust conclusions based on a very small number of patients, it is noteworthy that these four patients had lower DLCO than did those without clinical PVOD. Patient 4 in Table 2 is notable for having a relatively low mPAP and NT-ProBNP, a 6MWD that was greater than the mean distance walked by all patients, but hypoxaemia and low DLCO. Therefore we cautiously suggest that hypoxic patients with poor gas transfer should evoke a greater clinical suspicion of the possibility of developing PVOD.
Limitations
The current study may be underpowered and this may explain the lack of a significant effect of the presence of 52 CTS-PVOD on survival. Only a small number of patients had 52 CTS-PVOD, and thus the association between such findings and overt pulmonary oedema cannot be explored robustly. Finally, only a minority of our patients were treated with prostanoids, and we do not have histological diagnoses of PVOD. However all patients were followed to death and evidence of PVOD was rare even as disease progressed.
Supplementary data
Supplementary data are available at Rheumatology Online. 
